Table 2A.

Summary of inclusion criteria of clinical trials. Results are mean values.

Study	Control						Treatment
Study	Year	Age, yrs	Female, %	RF+, %	ESR	DAS28	Age, yrs	Female, %	RF+, %	ESR	DAS28
Monotherapy
Eberhardt⁵⁰	1996	53	63	80	36	—	50	52	67	32	—
Rau⁵¹	1997	54	60	68	41	—	57	72	54	41	—
Van Jaarsveld⁵²	2000	56	69	67	42	—	57	64	65	41	—
Choy¹⁸	2002	58	74	54	—	5.3	57	76	58		5
Monotherapy vs combination therapy
Boers¹	1997	49	52	72	—	—	50	66	78	—	—
Möttönen⁷	1999	48	66	66	39	—	47	58	70	37	—
Proudman⁵³	2000	50	55	79	31.4	5.1	51	65	80	39.1	5.4
Ferraccioli⁵⁴	2002	59	86	55	43	—	59	86	73	52	—
Gerards⁵⁵	2003	51	70	97	46	—	53	62	93	53	—
Wassenberg⁵⁶	2005	50	65	47	40	—	53	75	43	44.5	—
St. Clair⁵⁷	2004	50	75	71	43	6.7	50	68	73	44	6.7
Svensson²⁴	2005	59	63	66	—	5.4	51	65	66	—	5.28
Allaart³	2006	54	68	67	DAS 44	4.5	54	66	64	DAS 44	4.3
Breedveld⁶	2006	52	74	—	—	6.3	52	72		—	6.3
Choy²	2008	54	67	66	—	5.8	55	67	72	—	5.6
Emery⁴	2008	52	73	—	49	6.5	51	74	—	47.8	6.5
Hetland¹⁹	2006	51	70	59	27	5.5	53	64	70	28	5.3
Combination vs combination therapy
Verstappen⁵⁸	2007	53	66	62	39	—	54	69	66	36	—
Saunders⁵⁹	2008	55	79	72	45	6.9	55	76	69	36	6.8
Verschueren²⁰**	2008	55	65	52	DAS28	CRP 4.76	45	63	79	DAS28	CRP 5.28